Trials / Completed
CompletedNCT02805556
Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing
Study of the Absolute Bioavailability of BMS-626529 in Healthy Subjects Following Oral Dosing of BMS-663068 and Intravenous Dosing of BMS-626529
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
A phase I absolute bioavailability study of BMS-626529 following oral and intravenous dosing
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-663068 | Single oral dose of BMS-663068 |
| DRUG | BMS-626529 | Single intravenous dose of \[13C\]BMS 626529 |
Timeline
- Start date
- 2016-03-15
- Primary completion
- 2016-05-05
- Completion
- 2016-05-05
- First posted
- 2016-06-20
- Last updated
- 2017-07-21
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02805556. Inclusion in this directory is not an endorsement.